EQL Pharma ABOSTO:EQL -2.32%42 Gross Margin % is 28.28% as of Mar. 2026, which is 36% below its 10-year median of 44.06. GuruFocus rates OSTO:EQL with a GF Score™ of 42/100. The stock has 4 warning signs investors should review. Among 937 Drug Manufacturers companies, EQL Pharma AB ranks worse than 68.94% on this metric.
The historical rank and industry rank for EQL Pharma AB's Gross Margin % or its related term are showing as below:
OSTO:EQL'
s Gross Margin % Range Over the Past 10 Years
Min: 23.36 Med: 44.06 Max: 69.93
Current: 37.64
During the past 13 years, the highestGross Margin % of EQL Pharma AB was 69.93%. The lowest was 23.36%. And the median was 44.06%.
OSTO:EQL's Gross Margin % is ranked worse than 68.94% of 937
companies
in the Drug Manufacturers industry
Industry Median: 48.46
vs OSTO:EQL: 37.64
EQL Pharma AB had a gross margin of 28.28% for the quarter that ended in Mar. 2026 => Competition eroding margins
The 5-Year average Growth Rate of Gross Margin for EQL Pharma AB was 9.30% per year.
EQL Pharma AB (OSTO:EQL) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
EQL Pharma AB had a gross margin of 28.28% for the quarter that ended in Mar. 2026 => Competition eroding margins
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
EQL Pharma AB Gross Margin % Related Terms
EQL Pharma AB Gross Margin % Historical Data
* Premium members only.
The historical data trend for EQL Pharma AB's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, EQL Pharma AB's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
EQL Pharma AB Gross Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, EQL Pharma AB's Gross Margin % distribution charts can be found below:
* The bar in red indicates where EQL Pharma AB's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
EQL Pharma AB (OSTO:EQL) has a Gross Margin % of 28.28% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on EQL Pharma AB and its competitors. This is 36% below median its historical median of 44.06. Over the past decade, EQL Pharma AB's Gross Margin % has ranged from 23.36 to 69.93. According to the industry distribution chart, EQL Pharma AB ranks #646 out of 937 companies in the Drug Manufacturers industry, placing it in the top 68.9%.
Is EQL Pharma AB's Gross Margin % too high?
EQL Pharma AB's current Gross Margin % of 28.28% is 36% below median its 10-year median of 44.06. Over the past 10 years, this metric has ranged from a low of 23.36 to a high of 69.93. The Drug Manufacturers industry median Gross Margin % is 48.46. EQL Pharma AB's value of 28.28% is 41.6% below this industry median. Based on the distribution chart, EQL Pharma AB ranks #646 out of 937 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, EQL Pharma AB has a GF Score™ of 42/100, reflecting its overall financial health beyond just this single metric.
How does EQL Pharma AB's Gross Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, EQL Pharma AB ranks #646 out of 937 companies for Gross Margin %. This places EQL Pharma AB in the lower half of its industry. The industry median Gross Margin % is 48.46. EQL Pharma AB's value of 28.28% is 41.6% below this benchmark. Historically, EQL Pharma AB's own Gross Margin % has ranged from 23.36 to 69.93 over the past decade. While the company's 10-year median is 44.06 vs. the industry median of 48.46, EQL Pharma AB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Drug Manufacturers company?
The median Gross Margin % among Drug Manufacturers companies is 48.46, based on 937 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. EQL Pharma AB's current Gross Margin % of 28.28% is 41.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on EQL Pharma AB and its competitors. For the Drug Manufacturers industry, the median Gross Margin % is 48.46 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. EQL Pharma AB's current Gross Margin % is 28.28%, which is 36% below median its own 10-year median of 44.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is EQL Pharma AB stock overvalued right now?
EQL Pharma AB (OSTO:EQL) has a current Gross Margin % of 28.28%. The current Gross Margin % is 28.28%, which is 36% below median its 10-year median of 44.06 and 41.6% below the Drug Manufacturers industry median of 48.46. EQL Pharma AB's overall GF Score™ is 42/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For EQL Pharma AB (OSTO:EQL), the current Gross Margin % is 28.28% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
EQL Pharma AB is a pharmaceutical company focused on efficiently and thoughtfully developing and marketing generic drugs. The company operates in one segment, which is medicine. Its niche generics are divided into four parts based on four sales and marketing models: Retail, Hospital, Branded, and Tests. EQL Pharma specializes in identifying, developing, and selling generics, i.e., medicines that are medically equivalent to originator medicines. The company operates in Sweden, Denmark, Norway, Finland, the rest of Europe, and outside Europe, generating the majority of its revenue from Sweden.
42GF Score
Get the complete analysis for OSTO:EQL
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:EQL has been successfully added to your 
